Last reviewed · How we verify
NCT05803759: TEA-CART
The Effects of Allicor on Patients After Coronary Arteria Revascularization Treatment
Phase 4 trial testing Allicor in Myocardial Ischemia in 200 participants. Status unknown.
31 March 2024
Quick facts
| Lead sponsor | Institute for Atherosclerosis Research, Russia |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 200 |
| Start date | 10 April 2023 |
| Primary completion | 31 March 2024 |
| Estimated completion | 31 March 2025 |
| Sites | 1 location across Russia |
Drugs / interventions tested
- Allicor
- Placebo
Conditions studied
- Myocardial Ischemia — all drugs for Myocardial Ischemia →
- Coronary Artery Bypass Grafting — all drugs for Coronary Artery Bypass Grafting →
- Coronary Arteriosclerosis — all drugs for Coronary Arteriosclerosis →
- Percutaneous Coronary Revascularization — all drugs for Percutaneous Coronary Revascularization →
Sponsor
Institute for Atherosclerosis Research, Russia
Who can join
Adults 40 to 75, any sex, with Myocardial Ischemia or Coronary Artery Bypass Grafting. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Coronary revascularization interventions such as coronary artery bypass graft (CABG) and percutaneous coronary intervention (PCI) are the standard of surgical treatment of patients with myocardial ischemia. However, up to 30% of patients experience complications of varying degrees within 12 months after the revascularization, or need for second intervention. Thus, it is necessary to search for additional approaches to the postoperative treatment of patients in order to improve the long-term results of revascularization treatment. Substances of natural origin with an anti-atherosclerotic effect have a good potential. These substances, as dietary supplements, can be taken by patients for a long time in conjunction with other prescribed medicines and treatments. Another valuable direction of investigations is the search for predictors of long-term cardiovascular complications after revascularization, which can be markers of inflammation and heteroplasmy levels of the patient's mitochondrial genome. The purpose of this study is to determine whether the intake of dietary supplement Allicor at a daily dose of 300 mg affects the frequency of long-term postoperative cardiovascular complications and re-intervention in patients after revascularization operations on the coronary arteries. The second goal is assessing the relationship between the grade monocytes inflammatory response and the level of heteroplasmy of the mitochondrial genome of blood leukocytes with the frequency of cardiovascular complications and re-interventions.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05803759
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Allicor
Trials testing the same drug.
- NCT05813171 — The Effects of Allicor on Patients After Revascularization Treatment During a Year · Phase 4 · unknown
Other recruiting trials for Myocardial Ischemia
Currently open trials in the same condition.
- NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
- NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting
- NCT07241572 — Evaluation of Perioperative Myocardial Injury in Patients Undergoing Below-Knee Lower Extremity Surgery · recruiting
- NCT06681740 — Effectiveness of Inspiratory Muscle Training for People With Ischemic Heart Disease Revascularized by Percutaneous Trans · NA · recruiting
- NCT06570759 — Time for a Diagnostic Paradigm Shift From STEMI/NSTEMI to OMI/NOMI · NA · active not recruiting
Other Institute for Atherosclerosis Research, Russia trials
Trials by the same sponsor.
- NCT06590012 — Evaluating the Impact of 'Tertinat' on Patients with Atherosclerosis-Related Cardiovascular Diseases · Phase 2 · recruiting
- NCT05813171 — The Effects of Allicor on Patients After Revascularization Treatment During a Year · Phase 4 · unknown
- NCT03877523 — Cocarnit Effects on Macrophages Polarization · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05803759 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institute for Atherosclerosis Research, Russia
- Last refreshed: 19 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05803759.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing